安普利近(Rintatolimod) - 药物靶点：TLR3_在研适应症：慢性疲劳综合征，结直肠癌，前列腺腺癌_专利_临床

概要

基本信息

药物类型

ASO

别名

Ampligen、Atvogen、Rintamod

+ [5]

靶点

TLR3

作用方式

激动剂

作用机制

TLR3激动剂(Toll样受体3激动剂)

治疗领域

感染神经系统疾病皮肤和肌肉骨骼疾病+ [4]

在研适应症

慢性疲劳综合征结直肠癌前列腺腺癌+ [6]

非在研适应症

急性白血病慢性淋巴细胞白血病新型冠状病毒感染+ [8]

原研机构

AIM ImmunoTech, Inc.

在研机构

AstraZeneca PLC

AIM ImmunoTech, Inc.

非在研机构

Roswell Park Comprehensive Cancer Center

权益机构

Centre for Human Drug Research

Erasmus University Medical Center

Roswell Park Comprehensive Cancer Center

+ [1]

最高研发阶段批准上市

首次获批日期

阿根廷 (2017-01-01),

慢性疲劳综合征

最高研发阶段(中国)-

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C28H40N9O25P3

InChIKeyKNUXHTWUIVMBBY-JRJYXWDASA-N

CAS号38640-92-5

使用我们的RNA技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

26

项与安普利近相关的临床试验

NCT05494697

/ Suspended临床2期

A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

开始日期2026-06-01

申办/合作机构

AIM ImmunoTech, Inc.

[+1]

NCT04093323

/ Terminated临床2期IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-13

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT05756166

/ Terminated临床1/2期IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

开始日期2024-02-16

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与安普利近相关的临床结果

登录后查看更多信息

100 项与安普利近相关的转化医学

登录后查看更多信息

100 项与安普利近相关的专利（医药）

登录后查看更多信息

66

项与安普利近相关的文献（医药）

2024-08-15·Clinical cancer research : an official journal of the American Association for Cancer Research

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Article

作者: van Eijck, Casper H.J. ; van Eijck, Casper W.F. ; Mustafa, Dana A.M. ; Aerts, Joachim G.J.V. ; Kucukcelebi, Songul ; Willemsen, Marcella ; Fellah, Amine ; Vadgama, Disha ; Haddaoui, Hassana el

Abstract:

Purpose::

Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.

Experimental Design::

Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.

Results::

Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.

Conclusions::

This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

2023-04-01·Antiviral research

Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action

Article

作者: Daino, Gian Luca ; Strayer, David ; Mitchell, William M ; Distinto, Simona ; Tramontano, Enzo ; Paulis, Annalaura ; Corona, Angela

Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status. 100% protection from lethal EBOV-Zaire in Balb/c mice was achieved by rintatolimod (Ampligen) at the well tolerated human clinical dose of 6 mg/kg. The data indicate that the mechanism of action is rintatolimod's dual ability to act as both a competitive decoy for the IID domain of VP35 blocking viral dsRNA sequestration and as a pathogen-associated molecular pattern (PAMP) restricted agonist for direct TLR3 activation but lacking RIG-1-like cytosolic helicase agonist properties. These data show promise for rintatolimod as a prophylactic therapy against human Ebola outbreaks.

2023-01-01·American journal of cancer research

Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3.

Article

作者: Hofland, Leo J ; van den Bosch, Thierry Pp ; van Eijck, Casper Hj ; van Koetsveld, Peter M ; van Eijck, Casper Wf ; Doukas, Michail ; Haddaoui, Hassana El ; Mustafa, Dana Am

Pancreatic cancer has a dismal prognosis, and treatment options for patients with locally advanced or metastatic disease are limited. Early tumor progression after standard chemo- and or radiotherapy remains a major concern in managing these patients. Treating pancreatic cancer patients with the Toll-like receptor 3 (TLR-3) agonist rintatolimod (Ampligen^®) was effective in boosting the immune response. Rintatolimod acts via the TLR-3 receptor on several immune cells. However, the TLR-3 expression pattern in pancreatic cancer cells and how rintatolimod affects pancreatic cancer cells have not yet been investigated. The TLR-3 protein and mRNA expression were evaluated in thirteen PDAC tissue samples as well as in the human PDAC (hPDAC) cell lines CFPAC-1, MIAPaCa-2, and PANC-1 using immunohistochemistry and multiplexed gene expression analysis, respectively. The direct anti-tumor effects of rintatolimod were investigated using a proliferation and migration assay after different incubation time points with increasing concentrations of rintatolimod (ranging from 0.05 to 0.4 mg/ml). The TLR-3 protein and mRNA expression were heterogeneous between the PDAC tissue samples and the three hPDAC cell lines. TLR-3 protein and mRNA expression were high in CFPAC-1, moderate in MIAPaCa-2, and undetectable in PANC-1. Rintatolimod three-day treatment resulted in significantly reduced proliferation of CFPAC-1 cells compared to vehicle-treated control cells. In addition, after 24 hours, rintatolimod-treated CFPAC-1 cells showed less cell migration compared to vehicle-treated control cells, although this difference was not statistically significant. Lastly, we identified fifteen genes, altered with a Log₂ FOC > |1.0| in rintatolimod-treated CFPAC-1 cells, which were significantly related to three transcription factors (NFKB1, RELA, and SP1) regulating the TLR-3 signaling pathway. In conclusion, we propose that rintatolimod treatment might have a direct TLR-3-dependent anti-tumoral effect on pancreatic cancer cells expressing TLR-3.

169

项与安普利近相关的新闻（医药）

2025-12-30

·aimimmuno.com

AIM ImmunoTech Announces Stock Dividend

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025. Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders’ book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder’s behalf. The stock dividend is administered by EQ, the Company’s transfer agent. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

免疫疗法

2025-12-30

·BioSpace

AIM ImmunoTech Announces Stock Dividend

OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9, 2026 and will be distributed and allocated to DTCC on January 13, 2026. Resulting fractional shares will be rounded down and any resulting fractional shares remaining after the foregoing rounding down will be distributed cash to each stockholder and Alternate Securities holder who would otherwise have been entitled to receive such fractional shares, based on a share price of $1.305, which is the average of the high and low share price on December 29, 2025. Stockholders will not be required to take any action to receive the stock dividend. After the payment date, stockholders' book entry accounts will be credited with the additional shares that represent the stock dividend. Where shares are held in a brokerage account in the name of a broker, the additional shares will be distributed to the broker on the stockholder's behalf. The stock dividend is administered by EQ, the Company's transfer agent. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook . Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

免疫疗法

2025-12-10

·GlobeNewswire-Health Care

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancerOCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca’s Imfinzi® (durvalumab). The CEO Corner segment is now available here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com

免疫疗法

100 项与安普利近相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09661	安普利近	L03A	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性疲劳综合征	阿根廷	AIM ImmunoTech, Inc.	2017-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床2期	美国	AIM ImmunoTech, Inc.	2026-06-01
转移性胰腺癌	临床2期	荷兰	AstraZeneca PLC	2024-01-09
转移性胰腺癌	临床2期	荷兰	AIM ImmunoTech, Inc.	2024-01-09
转移性胰腺导管腺癌	临床2期	荷兰	AstraZeneca PLC	2024-01-09
转移性胰腺导管腺癌	临床2期	荷兰	AIM ImmunoTech, Inc.	2024-01-09
新冠肺炎后遗症	临床2期	美国	AIM ImmunoTech, Inc.	2023-06-30
结直肠癌	临床2期	-	AIM ImmunoTech, Inc.	2022-04-11
急性白血病	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
急性白血病	临床2期	美国	AIM ImmunoTech, Inc.	2020-11-17
慢性淋巴细胞白血病	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03734692 (SITC2025) 人工标引	临床2期	铂敏感性卵巢癌	24	IP cisplatin + IV Pembrolizumab + IP TLR3 ligand Rintatolimod	鑰壓鏇製構觸鏇襯餘鏇(鬱鹽觸糧鹽遞顧淵餘觸) = 鏇廠製願範壓糧願積製鹽獵夢繭繭淵醖鹽觸鹹 (構廠襯構網鏇鑰鬱構願 ) 更多	积极	2025-11-07
NCT05927142 (DURIPANC, GlobeNewswire) 人工标引	临床2期	转移性胰腺癌	14	rintatolimod + durvalumab	夢選鹹願顧獵願簾廠壓(網簾鹽繭構鬱糧餘繭繭) = 鹹鑰廠鹹願鏇鏇遞鑰醖鏇鏇襯憲製鏇顧憲齋餘 (淵夢範獵範獵壓壓餘淵 ) 更多	积极	2025-07-28
NCT03734692 (CTgov)	临床1/2期	复发性卵巢癌	24	cisplatin+Rintatolimod+Pembrolizumab	夢選築鹽遞蓋顧夢鏇衊 = 遞網構鑰膚壓鬱顧窪觸淵醖繭憲網艱襯構膚艱 (積憲廠鑰積獵窪蓋窪範, 築窪鑰淵製構願鏇艱願 ~ 鹹鑰衊糧衊鏇觸壓觸觸) 更多	-	2025-07-20
NCT05592418 (AMP-518, CTgov)	临床2期	新冠肺炎后遗症	80	Rintatolimod (Ampligen / Rintatolimod)	範製艱築選積窪鑰願壓(選願鹹糧鑰網淵製憲鬱) = 窪餘選觸廠遞遞網構願鑰顧選觸蓋衊淵鑰醖蓋 (艱繭鑰蓋鹹餘鏇鹽選遞, 9.31) 更多	-	2025-01-22
NCT05592418 (AMP-518, CTgov)	临床2期	新冠肺炎后遗症	80	Placebo / Normal Saline (Placebo / Saline)	範製艱築選積窪鑰願壓(選願鹹糧鑰網淵製憲鬱) = 網壓製簾遞鑰壓膚繭艱鑰顧選觸蓋衊淵鑰醖蓋 (艱繭鑰蓋鹹餘鏇鹽選遞, 7.51) 更多	-	2025-01-22
NCT05927142 (DURIPANC, NEWS 1 \| NEWS 2)	临床1/2期	转移性胰腺癌	-	度伐利尤单抗+Rintatolimod	窪衊簾夢積襯顧壓窪齋(簾願糧夢蓋簾鹽積顧觸) = 窪齋夢遞築獵夢顧選築鏇壓餘衊鹽壓網齋願壓 (築衊鑰糧鹽壓構糧窪艱 )	积极	2024-04-29
NCT05592418 (AMP-518, Corporate Publications) 人工标引	临床2期	新冠肺炎后遗症	66	Ampligen	積觸襯憲製鹽築製蓋獵(壓繭簾繭遞襯艱鑰淵淵) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. 簾繭範窪衊艱鬱獵鏇網 (鏇壓鹽齋衊鏇繭鹹壓襯 ) 更多	积极	2024-02-08
NCT05592418 (AMP-518, Corporate Publications) 人工标引	临床2期	新冠肺炎后遗症	66	Placebo		积极	2024-02-08
NCT03734692 (GlobeNewswire) 人工标引	临床2期	复发性卵巢癌	-	Ampligen+pembrolizumab	簾製淵獵選積襯範憲窪(製鹽獵壓鹹鑰醖鏇願艱) = Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors 獵餘襯鏇獵窪蓋膚蓋廠 (夢觸製鹽製襯築鏇蓋襯 )	积极	2023-11-08
NCT04081389 (Phase I study, CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	鹹廠壓獵製蓋醖製獵壓 = 觸鑰簾鏇選廠齋願顧醖衊夢範衊窪願醖鏇齋願 (艱遞窪築願顧齋淵顧獵, 選餘簾蓋構鏇製網憲夢 ~ 構觸築繭醖鑰窪淵範醖) 更多	-	2023-09-11
NCT04081389 (Phase I study, CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	鹹廠壓獵製蓋醖製獵壓 = 醖淵鑰鏇觸淵餘觸簾選衊夢範衊窪願醖鏇齋願 (艱遞窪築願顧齋淵顧獵, 獵築選積願遞衊鏇顧選 ~ 衊餘衊繭窪構廠壓蓋繭) 更多	-	2023-09-11
Corporate Publications 人工标引	临床1期	-	40	Rintatolimod	廠顧餘膚窪遞醖遞鬱觸(醖壓壓膚膚鹹齋糧膚鑰) = 觸壓衊餘鹽範選鹽構蓋鏇襯窪選醖糧選憲範鏇 (鹹鏇簾鹽構餘廠糧獵遞 )	积极	2022-12-08
Corporate Publications 人工标引	临床1期	-	40	Placebo	廠顧餘膚窪遞醖遞鬱觸(醖壓壓膚膚鹹齋糧膚鑰) = 築鹽齋選鏇願構遞糧願鏇襯窪選醖糧選憲範鏇 (鹹鏇簾鹽構餘廠糧獵遞 )	积极	2022-12-08
NCT04081389 (SITC2022) 人工标引	临床1期	三阴性乳腺癌 ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	廠願製餘願積醖製簾願(簾簾積衊鹹顧鑰製築鏇) = 鏇夢觸醖範廠膚積鬱淵淵範範顧醖獵積艱顧繭 (夢遞網遞繭鹽齋糧齋艱 ) 更多	积极	2022-11-01